Loading stock data…
DGX
$192.67-1.53 (-0.79%)
Market ClosedLast close May 1
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Quest Diagnostics Incorporated in the Healthcare sector is trading at $192.67. The stock is currently 10% below its 52-week high of $213.50, remaining 4.2% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why DGX maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$192.67
Potential Downside
8.3%
Whystock Fair Value$176.70
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Buy
Mean target$223.13+15.8%
Range$184.00 – $245.00
Fundamentals
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
22.52
Beta
Defensive asset. Lower volatility than the S&P 500.
0.65
Div Yield
Strong income play. Yield provides a meaningful total return floor.
169.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.25%
Volume
Today's trading volume
681,083
Recent News
2 Things Matter Most in Picking Winning Stocks, Says This Market Pro
Adam Parker’s Trivariate Research analyzes stocks from a macro, fundamental, and quantitative perspective.
Quest Diagnostics Debt Raise And ctDNA Alliance Spark Valuation Questions
Quest Diagnostics (NYSE:DGX) announced a US$500 million senior notes offering. The company also entered a multi year clinical partnership with City of Hope focused on advanced ctDNA testing. The partnership will use the Haystack MRD test for cancer trial patients, aiming to refine minimal residual disease monitoring. Quest Diagnostics operates as a large diagnostic information services provider, and this mix of capital markets activity and oncology collaboration puts both its financing and...
5 Must-Read Analyst Questions From Quest’s Q1 Earnings Call
Quest Diagnostics delivered first quarter results that exceeded Wall Street’s revenue and profit expectations, driven by broad-based demand for its clinical innovations and expansion into new areas like end-stage renal disease and brain health. Management attributed the organic growth to increased test volumes across physician, hospital, and consumer channels, alongside productivity gains from automation and artificial intelligence. CEO James Davis highlighted the strong adoption of advanced dia
These Companies Are Raising Guidance This Earnings Season
Both UnitedHealth and Quest Diagnostics have raised their current year outlooks, with each also seeing a favorable post-earnings reaction.
SkylineDx Presents Gene Expression Profiling for Skin Cancer Metastases
By Karen Roman SkylineDx said it can predict metastases and outperform existing staging systems for the country’s second most common type of skin cancer, Cutaneous Squamous Cell Carcinoma (CSCC). The results will be presented at the 22nd European Association of Dermato-Oncology Congress, held on April 23-25, 2026, in Prague and online. “This marks our first […]